HARMONY: a €40 million PROJECT FOR BETTER CARE OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES
After more than one year of preparations the agreement for the HARMONY project has been signed.
HARMONY will capture, integrate, analyze and harmonize anonymous patient data from high-quality multidisciplinary sources to unlock valuable knowledge on multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), myelodysplastic syndromes (MDS) and pediatric HMs.
The HARMONY project's final deliverable is a big data platform that will integrate disease information in order to better understand the diseases and how to treat most efficiently. HARMONY will achieve this from a pan-European perspective by uniting and aligning European stakeholders and key opinion leaders in the field. The project is made up of 51 partners from 11 European countries, including 7 pharmaceutical companies. The 5-year project will start in January 2017 and is funded through the Innovative Medicines Initiative (IMI); Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.
- HARMONY Press Release 1: INNOVATIVE MEDICINES INITIATIVE APPROVES € 40 million PROJECT FOR BETTER CARE OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES. January 9, 2017 (click here)
- HARMONY Press Release 2: HARMONY: Better care of patients with hematologic malignancies kicked off! January 19, 2017 (click here)
- HARMONY explained. Watch these short videos to learn more about the project. (click here)
For more information, please visit: http://www.imi.europa.eu/content/harmony
Contact information: Harmonyoffice@ibsal.es
THE INNOVATIVE MEDICINES INITIATIVE
The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the pharmaceutical industry association EFPIA.
It should be made clear in the text and layout that the communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.